Treatment Options for Hepatic Steatosis (Fatty Liver Disease)

Lifestyle Interventions

A hypocaloric diet (500-1000 kcal energy deficit) is recommended to achieve weight loss of 500-1000g/week, according to the American Association for the Study of Liver Diseases, for patients with hepatic steatosis 1
Loss of at least 3-5% of body weight improves steatosis, while greater weight loss (up to 10%) may be needed to improve necroinflammation, as recommended by the American Gastroenterological Association 2, 3, 4
Avoid fructose-containing beverages and foods, as suggested by the European Association for the Study of the Liver 1
Limit alcohol consumption below risk threshold (30g for men, 20g for women) or consider complete abstinence, as recommended by the American College of Gastroenterology 1

Patients without NASH or fibrosis should only receive counseling for healthy diet and physical activity without pharmacotherapy, according to the European Association for the Study of the Liver 1
Pharmacological treatment should be considered for patients with progressive NASH (bridging fibrosis and cirrhosis), as recommended by the American Association for the Study of Liver Diseases 1
Metformin: Not recommended as a specific treatment for liver disease in adults with NASH as it has no significant effect on liver histology, according to the American Gastroenterological Association 4

Patients should be risk-stratified to determine appropriate management, with low-risk patients (FIB-4 score <1.3, LSM <8.0 kPa, or liver biopsy fibrosis stage F0-F1) focusing on lifestyle interventions, as recommended by the American College of Gastroenterology 5
Liver biopsy remains the gold standard for characterizing liver histology but should be reserved for patients who would benefit most from diagnostic, therapeutic guidance, and prognostic perspectives, according to the American Association for the Study of Liver Diseases 2, 3
Non-invasive tests like NAFLD Fibrosis Score can help identify patients at risk for advanced fibrosis, as suggested by the European Association for the Study of the Liver 2, 6

Multidisciplinary care involving primary care physicians, endocrinologists (for patients with diabetes), and gastroenterologists/hepatologists is recommended for patients with complex metabolic profiles, according to the American Gastroenterological Association 5
Addressing all metabolic risk factors is crucial, as cardiovascular disease is the main driver of morbidity and mortality in patients with NAFLD before the development of cirrhosis, as recommended by the American Heart Association 5

Loss of 3-5% of body weight improves steatosis, while greater weight loss (7-10%) is needed to improve inflammation and potentially fibrosis, according to the Clinical and Molecular Hepatology guidelines 7
All patients with NAFLD need lifestyle modifications and treatment for comorbidities regardless of disease severity, as recommended by the Clinical and Molecular Hepatology guidelines 7
Pharmacologic treatment should be considered selectively based on risk stratification, with higher risk patients (NASH or ≥F2 fibrosis) considered for additional pharmacologic treatment, according to the Clinical and Molecular Hepatology guidelines 7

Consider GLP-1 agonists for diabetes management, which can be effective for NASH recovery, as suggested by the Clinical and Molecular Hepatology guidelines 7
Avoid sulfonylureas and insulin if possible, as they may increase the risk of hepatocellular carcinoma (HCC), according to the Clinical and Molecular Hepatology guidelines 7
Statins are safe and effective and may reduce the risk of developing HCC by 37%, as reported by the Clinical and Molecular Hepatology guidelines 7

Patients with liver cirrhosis associated with NAFLD need HCC surveillance, as recommended by the Clinical and Molecular Hepatology guidelines 7
To reduce the development of HCC, smoking cessation, alcohol abstinence, and weight loss are strongly recommended, according to the Clinical and Molecular Hepatology guidelines 7

Weight loss rate matters: Gradual weight loss (maximum 1kg/week) improves NASH and NAFLD activity score, while rapid weight loss may worsen liver disease, as suggested by the Clinical and Molecular Hepatology guidelines 7